FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV4437883605
Express Mail Label Number

January 14, 2005
Date of Doposit

Form PTO-1390-MOD U. S. Department of Commerce Patent and Trademark Office ATTORNEY'S DOCKET NUMBER (REV 10-96) BP/G-32983A/LEK U.S. APPLICATION NO. (If known, see 37 CFR 1.5) TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) 10/521298 CONCERNING A FILING UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. PRIORITY DATE CLAIMED INTERNATIONAL FILING DATE PCT/SI03/00023 17 July 2002 (17.07.02) 14 July 2003 (14.07.03) TITLE OF INVENTION STABLE PHARMACEUTICAL COMPOSITION COMPRISING ERYTHROPOIETIN APPLICANT(S) FOR DO/EO/US VUKMIROVIC ET AL. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2 This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.

3. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority 4. date. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is transmitted herewith (required only if not transmitted by the International Bureau). has been transmitted by the International Bureau. (See Form PCT/IB/308) is not required, as the application was filed in the United States Receiving Office (RO/US). A translation of the International Application into English (35 U.S.C. 371(c)(2)). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)). are transmitted herewith (required only if not transmitted by the International Bureau). have been transmitted by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)). A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 20. below concern document(s) or information included.

20.

Other items or information: Unexecuted Declaration and Power of Attorney

11. 2	Z	An information Disclosure Statement under 37 CFR 1.97 and 1.98.
12.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. D		A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment.
14. 🛭	₃	An Application Data Sheet under 37 CFR 1.76.
15. [A substitute specification.
16.		A change of power of attorney and/or address letter.
17.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.
18.		A second copy of the published International Application under 35 U.S.C. 154(d)(4).
19.		A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).

U.S. APPLICATION NO ((1/17) or							POCKET NUMBER				
21. The following	CALCULATIONS PTO USE ONLY										
a) Basic natior											
b) Examination											
c) Search fee .		•									
	\$ 1000										
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.											
Total Sheets	Extra sheets			Number of each additional 50 or fraction thereof (round up to a whole number)							
29 - 100 =	0	/50 =		0	, , , , , , , , , , , , , , , , , , ,	X \$ 250	\$				
Surcharge of \$130 fo months from the earli	\$										
CLAIMS	N	UMBER	FILED	NUMBER EXTRA		ATE					
Total claims		.0	- 20 =	0	X \$	50	\$				
Independent claims		1	- 3 =		X \$ + \$	200 360	\$				
MULTIPLE DEPEND	\$										
TOTAL OF ABOVE CALCULATIONS = \$ 1000											
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be											
filed (Note 37 CFR 1.9, 1.27, 1.28). \$											
	\$ 1000										
Processing fee of \$130 for furnishing the English translation later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(f)). + \$											
						IAL FEE =	\$ 1000				
Fee for recording the by an appropriate cov	accompanied +	\$									
			·	TOTAL FI	EES ENCL	OSED =	\$ 1000				
	Amount to be:	1 '									
							charged	 			
a. A check in the	ne amoun	t of \$		to cover the above fee	es is enclose	d.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.											
Send all correspondence to the address associated with Customer No. 001095, which is currently:											
Novartis Corporate Intellectual Property One Health Plaza, Building 104/3 East Hanover, NJ 07936-1080 John J. Thallemer Attorney for Applicant Reg. No. 34,940 (862) 778-7945											